Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Impact · against what's priced in

Serina Therapeutics receives a significant positive catalyst as it secures up to $30 million in funding at a 68% premium to market price, extending its runway into 2H 2027. The funding and the appointment of a high-profile Co-Chairman provide both financial stability and strategic credibility to advance its Parkinson's trial via a capital-efficient regulatory pathway.

SER+0.70

No priced-in read yet